



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		COMPLETE IF KNOWN			
		Application Number	10/507,237		
		Filing Date	September 9, 2004		
		First Named Inventor	Ermini, Emilio A. et al.		
		Group Art Unit	1648		
		Examiner Name			
Sheet	1	of	1	Attorney Docket Number	21051 YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/BB/		Pinto, A. et al. "Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous EI-Deleted Adenoviral Vaccine Carriers", The Journal of Immunology, 2003, Vol. 171, pp. 6774-6779
/BB/		Moffatt, S. et al. "Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non-Human Adenoviruses: Implications in Gene Therapy", Virology, 2000, Vol. 272, pp. 159-167
/BB/		Ramshaw, I. et al. "The prime-boost strategy: exciting prospects for improved vaccination", Trends Immunology Today, 2000, Vol. 21, pp. 163-165

Examiner Signature	/Benjamin Blumel/	Date Considered	06/15/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., 7/12/2005

Substitute for form 1449A/PTO				COMPLETE IF KNOWN	
INFORMATION DISCLOSURE			Application Number	10/507,237	
STATEMENT BY APPLICANT			Filing Date	September 9, 2004	
(use many sheets as necessary)			First Named Inventor	Emini, Emilio A. et al.	
			Group Art Unit		
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	21051YP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
/BB/		2003/0138459		Wang, D. et al.	07/24/2003

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/BB/		WO	04/037294		Crucell Holland B.V.	05/06/2004
		WO	03/031588		Merck & Co., Inc.; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.	04/17/2003
		WO	02/022080		Merck & Co., Inc.	03/21/2002
		WO	01/02607		Merck & Co., Inc.	01/11/2001
		WO	00/70071		Introgene B.V.	11/23/2000
/BB/		WO	96/21015		Chiron Viagene, Inc.	07/11/1996

Examiner Signature	/Benjamin Blumel/	Date Considered	06/15/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP § 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc., 09/03/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

COMPLETE IF KNOWN



(use many sheets as necessary)

2

of

2

Application Number	10/507,237
Filing Date	September 9, 2004
First Named Inventor	Emini, Emilio A. et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21051YP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/BB/		Barnett, S. et al. "Prime-Boost Immunization Strategies against HIV", AIDS Research and Human Retroviruses, 1998, Vol. 14, Supplement 3, pp. S-299-S-309
		Chen, P. et al. "Effective repeat administration with adenovirus vectors to the muscle", Gene Therapy, 2000, Vol. 7, pp. 587-595
		Huang, Y. et al. "Human Immunodeficiency Virus Type 1-Specific Immunity after Genetic Immunization Is Enhanced by Modification of Gag and Pol Expression", Journal of Virology, 2001, Vol. 75, pp. 4947-4951
		Mack, C. et al. "Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype", Human Gene Therapy, 1997, Vol. 8, pp. 99-109
		Mastrangeli, A. et al. "'Sero-Switch' Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype", Human Gene Therapy, 1996, Vol. 7, pp. 79-87
		Morral, N. et al. "Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons", Proc. Natl. Acad. Sci. USA, 1999, Vol. 96, pp. 12816-12821
		Nan, X. et al. "Development of an Ad7 cosmid system and generation of an Ad7DE13HIVDmn env/rev recombinant virus", Gene Therapy, 2003, Vol. 10, pp. 326-336
		Natuk, R. et al. "Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model", Proc. Natl. Acad. Sci., USA, 1992, Vol. 89, pp. 7777-7781
		Natuk, R. et al. "Adenovirus Vectored Vaccines", Developments in Biological Standardization, 1994, Vol. 82, pp. 71-77
		Natuk, R. et al. "Immunogenicity of Recombinant Human Adenovirus-Human Immunodeficiency Virus Vaccines in Chimpanzees", AIDS Research and Human Retroviruses, 1993, Vol. 9, pp. 395-404
		Patterson, L. et al. "Potent, Persistent Cellular Immune Responses Elicited by Sequential Immunization of Rhesus Macaques with Ad5 Host Range Mutant Recombinants Encoding SIV Rev and SIV Nef", DNA and Cell Biology, 2002, Vol. 21, pp. 627-635
		Shiver, J. et al. "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", Nature, 2002, Vol. 415, pp. 331-335
/BB/		Yoshida, T. et al. "Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols", Clin. Exp. Immunol., 2001, Vol. 124, pp. 445-452

Examiner Signature	/Benjamin Blumel/	Date Considered	06/15/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/03/2003